Clinical Trial Update: Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of tazemetostat plus venetoclax for relapsed/refractory non-Hodgkin lymphoma has been terminated, including diffuse large B‑cell lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Tazemetostat (tazemetostat)
• Venetoclax (venetoclax)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | Phase 1 | Status: TERMINATED